Most Read Articles
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
2 days ago
Weight suppression appears to result in future onset of eating disorders characterized by dietary restriction or compensatory weight control behaviours, suggesting weight-suppressed women represent an at-risk group that may benefit from selective prevention programmes, a study has found.
3 days ago
Nocturia is a risk factor for mortality, according to the results of the Nagahama Study, which boasts of a low incidence of missing data and high representation of the general population.

Improving survival with CDK4/6 inhibitors in postmenopausal HR+/HER2-metastatic breast cancer patients

Rachel Soon
Medical Writer
28 Feb 2018

Since the US FDA’s approval of the first cyclin-dependent kinase (CDK) inhibitor in February 2015, the molecules continue to be put to the test as part of the treatment regimen for patients with oestrogen receptor-positive metastatic breast cancers (ER+ MBC), whether as first- or second-line therapies. While overall survival data has yet to mature from clinical trials, the intermediate results appear to support the present use of CDK 4/6 in combination with endocrine therapy in delaying further onset of the disease.

Recent updates on CDK 4/6 trials were reviewed and discussed at the recent European Society for Medical Oncology (ESMO) Congress 2017 in Madrid, Spain, by Dr Alessandra Gennari, medical director of the Division of Medical Oncology of Galliera Hospital, Genoa, Italy; as well as at the American Society of Clinical Oncology (ASCO) 2017 Annual Meeting in Chicago, USA, by Dr Ingrid A. Mayer, clinical director of the Breast Cancer Research Program at Vanderbilt-Ingram Cancer Center, Nashville, USA.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
2 days ago
Weight suppression appears to result in future onset of eating disorders characterized by dietary restriction or compensatory weight control behaviours, suggesting weight-suppressed women represent an at-risk group that may benefit from selective prevention programmes, a study has found.
3 days ago
Nocturia is a risk factor for mortality, according to the results of the Nagahama Study, which boasts of a low incidence of missing data and high representation of the general population.